May 18, 2021 RUC-4 (CeleCor Therapeutics), an investigational glycoprotein IIb/IIIa inhibitor (GPI) administered by subcutaneous injection, provides rapid and powerful platelet inhibition in patients with STEMI, according to findings from Cel-02, a phase IIa study. Average platelet inhibition 15 minutes after the injection increased across three doses, from 77.5% with the lowest dose to 87.5% with the middle dose and 91.7% with the highest dose ( P = 0.002 for trend), Jurriën ten Berg, MD, PhD (St. Antonius Hospital, Nieuwegein, the Netherlands), reported during the virtual EuroPCR 2021. RUC-4 was well tolerated among the 27 patients in the trial, with one injection-site reaction and two major bleeds, both related to perforation as the guidewire passed through a side branch of the radial artery.